Search Results - "Tomcikova, D."

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO by Dell’Aquila, E., Cremolini, C., Zeppola, T., Lonardi, S., Bergamo, F., Masi, G., Stellato, M., Marmorino, F., Schirripa, M., Urbano, F., Ronzoni, M., Tomasello, G., Zaniboni, A., Racca, P., Buonadonna, A., Allegrini, G., Fea, E., Di Donato, S., Chiara, S., Tonini, G., Tomcikova, D., Boni, L., Falcone, A., Santini, D.

“…Neutrophil/lymphocyte ratio (NLR), defined as absolute neutrophils count divided by absolute lymphocytes count, has been reported as poor prognostic factor in…”
Get full text

Why is it necessary to examine retina when the patient suffers from aplastic anemia? by Tomcikova, D, Gerinec, A, Busanyova, B, Gresikova, M, Biskup, S, Hortnagel, K

“…To inform about a case of Revesz syndrome (RS) with initial ophthalmological symptomatology of severe proliferative vitreoretinopathy of the left eye (LE)…”
Get full text

Incomprehensible treatment of retinoblastoma with high doses of vitamin C by Tomcikova, D, Gerinec, A, Busanyova, B, Husakova, K, Kuniak, M, Autrata, R

“…To inform about a case of neglected retinoblastoma that was left untreated for more than 3 years by parents. During this time period the local finding worsened…”
Get full text

PD-004Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study by Marmorino, F, Cremolini, C, Loupakis, F, Antoniotti, C, Barbara, C, Dargenio, F, Miraglio, E, Masi, G, Salvatore, L, Schirripa, M, Borelli, B, Marcucci, L, Antonuzzo, L, Chiara, S, Banzi, C, Amoroso, D, Bonetti, A, Martignetti, A, Paris, M, Boni, L, Tomcikova, D, Falcone, A

Get full text

F-41 Sorafenib for hepatocellular carcinoma (HCC) in patients with established cirrhosis: impact of the type of recruiting unit and predictors of survival by Inghilesi, A, Antonuzzo, L, Gallori, D, Forte, P, Tomcikova, D, Arena, U, Colagrande, S, Pradella, S, Fani, B, Gianni, E, Boni, L, Laffi, G, Di Costanzo, F, Marra, F

Get full text

Relationship between high aortic pulse pressure and extension of coronary atherosclerosis in males by Pařenica, J, Kala, P, Jarkovský, J, Poloczek, M, Boček, O, Jeřábek, P, Neugebauer, P, Vytiska, M, Pařenicová, I, Tomčíková, D, Pávková Goldbergová, M, Spinar, J

“…A high pulse pressure (PP) is a marker of increased artery stiffness and represents a well-established independent predictor for cardiovascular morbidity and…”
Get full text

Trabectedin in combination with pegylated liposomal doxorubicin for patients with ovarian cancer by Tavella, K., Villanucci, A., Vannini, L., Montelatici, S., Lavacchi, D., Boni, L., Tomcikova, D., Amunni, G., Mazzei, T.

Get full text

Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study by Marmorino, F., Cremolini, C., Loupakis, F., Salvatore, L., Masi, G., Barbara, C., Dargenio, F., Miraglio, E., Ginocchi, L., Antonuzzo, L., Moretto, R., Schirripa, M., Chiara, S., Banzi, C., Amoroso, D., Bonetti, A., Martignetti, A., Paris, M., Boni, L., Tomcikova, D., Falcone, A.

Get full text

PD-004 Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study by Marmorino, F., Cremolini, C., Loupakis, F., Antoniotti, C., Barbara, C., Dargenio, F., Miraglio, E., Masi, G., Salvatore, L., Schirripa, M., Borelli, B., Marcucci, L., Antonuzzo, L., Chiara, S., Banzi, C., Amoroso, D., Bonetti, A., Martignetti, A., Paris, M., Boni, L., Tomcikova, D., Falcone, A.

Get full text

O-011 Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO by Antoniotti, C., Cremolini, C., Loupakis, F., Bergamo, F., Grande, R., Tonini, G., Garattini Silvio, K., Masi, G., Battaglin, F., Lucchesi, S., Salvatore, L., Corsi, D., Di Fabio, F., Banzi, M., Moretto, R., Sensi, E., Rossini, D., Tomcikova, D., Fontanini, G., Zagonel, V., Boni, L., Falcone, A.

Get full text

O-011Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO by Antoniotti, C, Cremolini, C, Loupakis, F, Bergamo, F, Grande, R, Tonini, G, Garattini Silvio, K, Masi, G, Battaglin, F, Lucchesi, S, Salvatore, L, Corsi, D, Di Fabio, F, Banzi, M, Moretto, R, Sensi, E, Rossini, D, Tomcikova, D, Fontanini, G, Zagonel, V, Boni, L, Falcone, A

Get full text

ONE YEAR OUTCOME OF ACUTE HEART FAILURE PATIENTS WITH HYPERTENSION AS UNDERLYING DISEASE: PP.1.22 by Felsoci, M, Miklik, R, Parenica, J, Tomcikova, D, Spinar, J

Get full text

Folfoxiri with or Without Bevacizumab (Bev) As First-Line Treatment of Metastatic Colorectal Cancer (Mcrc): a Propensity Score-Based Analysis by Cremolini, C., Loupakis, F., Rossini, D., Masi, G., Salvatore, L., Barbara, C., Brunetti, I.M., Antoniotti, C., Granetto, C., Cortesi, E., Chiara, S., Vitello, S., Lonardi, S., Ciuffreda, L., Tomasello, G., Ronzoni, M., Buonadonna, A., Tomcikova, D., Boni, L., Falcone, A.

Get full text

518PFOLFOXIRI WITH OR WITHOUT BEVACIZUMAB (BEV) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): A PROPENSITY SCORE-BASED ANALYSIS by Cremolini, C., Loupakis, F., Rossini, D., Masi, G., Salvatore, L., Barbara, C., Brunetti, I.M., Antoniotti, C., Granetto, C., Cortesi, E., Chiara, S., Vitello, S., Lonardi, S., Ciuffreda, L., Tomasello, G., Ronzoni, M., Buonadonna, A., Tomcikova, D., Boni, L., Falcone, A.

“…Abstract Aim: A phase III trial by the GONO group showed that the triplet FOLFOXIRI increased RECIST response rate (RR), PFS and OS, as compared to an…”
Get full text

Subgroup Analyses in RAS Mutant, BRAF Mutant and “ALL WT” Metastatic Colorectal Cancer Patients Treated with Folfoxiri Plus Bevacizumab (BEV) or Folfiri Plus BEV in the Tribe Study by Cremolini, C., Loupakis, F., Lonardi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., Tonini, G., Valsuani, C., Chiara, S., Boni, C., Marcucci, L., Negri, F.V., Barone, C., Vitello, S., D'Amico, M., Granetto, C., Antoniotti, C., Salvatore, L., Fontanini, G., Tomcikova, D., Boni, L., Falcone, A.

Get full text

PCV16 INPATIENT MANAGEMENT AND COSTS OF ACUTE CORONARY SYNDROMES IN FACULTY HOSPITAL: COMPARISON OF STEMI AND NON-STEMI by Ondrackova, B, Felsoci, M, Parenica, J, Spinar, J, Sulcova, A, Tomcikova, D

Get full text

PCV124 COST OF CORONARY ARTERY BYPASS GRAFT (CABG) IN ACUTE HEART FAILURE PATIENTS IN THE CZECH REPUBLIC by Ondrackova, B, Miklik, R, Parenica, J, Spinar, J, Sulcova, A, Tomcikova, D

Get full text

PCV67 CLINICAL CHARACTERISTICS, MEDICATION AND COSTS IN ACUTE HEART FAILURE PATIENTS IN THE CZECH REPUBLIC by Ondrackova, B, Miklik, R, Parenica, J, Spinar, J, Pavlik, T, Tomcikova, D

Get full text

LATE CHOROIDAL NEOVASCULAR COMPLICATIONS IN A PATIENT TREATED FOR RETINOBLASTOMA. A CASE REPORT by Popová, V, Tomčíková, D, Bušányová, B, Hodálová, K, Havalda, D, Gerinec, A

“…Case report of choroidal neovascularization (CNV) detection in patient who was treated for bilateral retinoblastoma in early childhood. Patient at 1.5 years of…”
Get more information

EFFECT OF MULTIPLE VARIABLES ON THE REFRACTIVE ERROR AFTER CATARACT SURGERY by Popov, I, Valašková, J, Krásnik, V, Tomčíková, D

“…To analyze refractive results after cataract surgery in relation to used type of monofocal intraocular lens, calculation formula, to age, gender and…”
Get more information